Core Viewpoint - The collaboration between Haixiang Pharmaceutical and Wanbangde Pharmaceutical Group focuses on developing innovative drugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, leveraging each company's strengths to enhance their market competitiveness [1] Group 1: Collaboration Details - Haixiang Pharmaceutical signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical on January 12, 2023 [1] - The initial collaboration will focus on the WP205 product, which has received orphan drug designation, and its research and commercialization [1] - Future cooperation will involve small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) in areas such as raw materials and formulations [1] Group 2: Strategic Implications - The partnership aims to effectively integrate resources and complement each other's strengths in the innovative drug sector [1] - Haixiang's involvement in the neurodegenerative disease drug development will expand and deepen its presence in the peptide drug field [1] - This collaboration is expected to enhance Haixiang's existing research pipeline and positively impact its innovative development, thereby improving future market competitiveness [1]

Core Viewpoint - Haisheng Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to collaborate on the development of treatments for amyotrophic lateral sclerosis (ALS) [1] Group 1: Agreement Details - The agreement was signed on January 12, 2026, and focuses initially on the WP205 product, which has already received orphan drug designation [1] - Haisheng Pharmaceutical will invest 150 million yuan, which will be paid in phases according to the agreement [1] - Upon successful collaboration, Haisheng Pharmaceutical will receive 15% of the global commercialization revenue from the WP205 product [1] Group 2: Future Collaboration - The partnership will later expand to include the development of small molecule cyclic peptide agonists, involving both raw materials and formulations [1] - The agreement is subject to approval by the shareholders' meeting of Wanbangde Pharmaceutical Holdings Group Co., Ltd. [1]